Have you been diagnosed with Stage III non-small cell lung cancer? Is your cancer advanced and not able to to removed? If so, you might be able to participate in a study that looks at a study drug to see if it can help the radiation treatment work better against your cancer.

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

If you have liver cirrhosis or chronic hepatitis B infection, you may qualify to participate in a research study that compares the effectiveness of two liver cancer screening methods. Please contact the study team to get more information. Compensation provided.

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Do you have non small cell lung cancer? Are you currently not on any other treatments for your cancer? If you answered yes, you may be able to take part in a lung cancer medication study.

In this study, we want to test a new web application we are creating. The app will help users find important information about digital health resources and how ready a community is to use them.

To conduct a pilot trial to determine feasibility and acceptability of the refined PREVAIL model in at least 50 adults with rheumatoid arthritis.

In this study, we want to learn about people who have lower levels of a type of blood cell called neutrophils but are still healthy. We want to find the normal neutrophil count in these people. This will help doctors and patients avoid unnecessary tests.